18.53 USD
-0.88 (-4.53%)
18.4 USD
-0.13 (-0.7%)
Overall CDNA gets a fundamental rating of 6 out of 10. We evaluated CDNA against 531 industry peers in the Biotechnology industry. CDNA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CDNA is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
CDNA had positive earnings in the past year.
CDNA had a positive operating cash flow in the past year.
In the past 5 years CDNA reported 4 times negative net income.
In multiple years CDNA reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of CDNA (14.06%) is better than 94.95% of its industry peers.
Looking at the Return On Equity, with a value of 19.53%, CDNA belongs to the top of the industry, outperforming 95.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROIC | N/A |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 16.97%, CDNA belongs to the best of the industry, outperforming 92.90% of the companies in the same industry.
With an excellent Gross Margin value of 67.62%, CDNA belongs to the best of the industry, outperforming 80.37% of the companies in the same industry.
In the last couple of years the Gross Margin of CDNA has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
2. Health
2.1 Basic Checks
CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDNA has been increased compared to 1 year ago.
Compared to 5 years ago, CDNA has more shares outstanding
There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CDNA has an Altman-Z score of 3.50. This indicates that CDNA is financially healthy and has little risk of bankruptcy at the moment.
CDNA has a better Altman-Z score (3.50) than 69.72% of its industry peers.
CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 3.5 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
A Current Ratio of 3.03 indicates that CDNA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.03, CDNA is doing worse than 64.67% of the companies in the same industry.
CDNA has a Quick Ratio of 2.75. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.75, CDNA is not doing good in the industry: 66.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 242.11% over the past year.
Measured over the past years, CDNA shows a very strong growth in Earnings Per Share. The EPS has been growing by 37.47% on average per year.
Looking at the last year, CDNA shows a quite strong growth in Revenue. The Revenue has grown by 14.46% in the last year.
The Revenue has been growing by 21.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
3.2 Future
The Earnings Per Share is expected to grow by 38.18% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 13.01% on average over the next years. This is quite good.
EPS Next Y25.04%
EPS Next 2Y30.7%
EPS Next 3Y33.39%
EPS Next 5Y38.18%
Revenue Next Year12.7%
Revenue Next 2Y12.35%
Revenue Next 3Y11.91%
Revenue Next 5Y13.01%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 28.51, which means the current valuation is very expensive for CDNA.
Based on the Price/Earnings ratio, CDNA is valued cheaply inside the industry as 92.71% of the companies are valued more expensively.
CDNA's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.49.
CDNA is valuated rather expensively with a Price/Forward Earnings ratio of 20.09.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 94.58% of the companies listed in the same industry.
CDNA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.69.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.51 | ||
| Fwd PE | 20.09 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, CDNA is valued cheaply inside the industry as 94.02% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.17 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CDNA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as CDNA's earnings are expected to grow with 33.39% in the coming years.
PEG (NY)1.14
PEG (5Y)0.76
EPS Next 2Y30.7%
EPS Next 3Y33.39%
5. Dividend
5.1 Amount
CDNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
18.53
-0.88 (-4.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.08%
Inst Owner Change-1.67%
Ins Owners2.49%
Ins Owner Change1.63%
Market Cap953.00M
Revenue(TTM)358.00M
Net Income(TTM)60.76M
Analysts80
Price Target23.46 (26.61%)
Short Float %14.07%
Short Ratio6.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.85%
Min EPS beat(2)-18.08%
Max EPS beat(2)93.77%
EPS beat(4)3
Avg EPS beat(4)37.25%
Min EPS beat(4)-18.08%
Max EPS beat(4)93.77%
EPS beat(8)7
Avg EPS beat(8)226.86%
EPS beat(12)11
Avg EPS beat(12)161.16%
EPS beat(16)12
Avg EPS beat(16)102.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.62%
Min Revenue beat(2)-6.22%
Max Revenue beat(2)2.98%
Revenue beat(4)2
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)2.98%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)8
Avg Revenue beat(12)5.96%
Revenue beat(16)8
Avg Revenue beat(16)3.77%
PT rev (1m)2.22%
PT rev (3m)2.22%
EPS NQ rev (1m)6.23%
EPS NQ rev (3m)6.9%
EPS NY rev (1m)23.74%
EPS NY rev (3m)18.64%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)0.16%
Revenue NY rev (1m)1.23%
Revenue NY rev (3m)0.96%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.51 | ||
| Fwd PE | 20.09 | ||
| P/S | 2.66 | ||
| P/FCF | 26.17 | ||
| P/OCF | 22.39 | ||
| P/B | 3.06 | ||
| P/tB | 4.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.65
EY3.51%
EPS(NY)0.92
Fwd EY4.98%
FCF(TTM)0.71
FCFY3.82%
OCF(TTM)0.83
OCFY4.47%
SpS6.96
BVpS6.05
TBVpS4.62
PEG (NY)1.14
PEG (5Y)0.76
Graham Number9.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.06% | ||
| ROE | 19.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 16.97% | ||
| GM | 67.62% | ||
| FCFM | 10.17% |
ROA(3y)-14.72%
ROA(5y)-10.93%
ROE(3y)-25.57%
ROE(5y)-18.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y0.9%
F-Score7
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.35% | ||
| Cap/Sales | 1.71% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 59.94% | ||
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.75 | ||
| Altman-Z | 3.5 |
F-Score7
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)106.55%
Cap/Depr(5y)139.53%
Cap/Sales(3y)4.27%
Cap/Sales(5y)5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.11%
EPS 3Y23.03%
EPS 5Y37.47%
EPS Q2Q%100%
EPS Next Y25.04%
EPS Next 2Y30.7%
EPS Next 3Y33.39%
EPS Next 5Y38.18%
Revenue 1Y (TTM)14.46%
Revenue growth 3Y4.04%
Revenue growth 5Y21.3%
Sales Q2Q%20.72%
Revenue Next Year12.7%
Revenue Next 2Y12.35%
Revenue Next 3Y11.91%
Revenue Next 5Y13.01%
EBIT growth 1Y37.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year156.58%
EBIT Next 3Y73.54%
EBIT Next 5Y67.07%
FCF growth 1Y364.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1603.82%
OCF growth 3YN/A
OCF growth 5YN/A
CAREDX INC / CDNA FAQ
What is the ChartMill fundamental rating of CAREDX INC (CDNA) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDNA.
Can you provide the valuation status for CAREDX INC?
ChartMill assigns a valuation rating of 5 / 10 to CAREDX INC (CDNA). This can be considered as Fairly Valued.
What is the profitability of CDNA stock?
CAREDX INC (CDNA) has a profitability rating of 4 / 10.
What is the valuation of CAREDX INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CAREDX INC (CDNA) is 28.51 and the Price/Book (PB) ratio is 3.06.